PMID 2858709 Clinical Trial priligy review The aromatase inhibitors are superior to tamoxifen in both efficacy and toxicity, and have the potential to reduce receptor negative tumors by synergy with COX 2 inhibitors
PMID 2858709 Clinical Trial priligy review The aromatase inhibitors are superior to tamoxifen in both efficacy and toxicity, and have the potential to reduce receptor negative tumors by synergy with COX 2 inhibitors